Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B
2
조회
0
다운로드
8
인용
0
참고문헌
키워드
초록
Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide epidemic, and is frequently found in patients with chronic hepatitis B (CHB). We investigated the impact of histologically proven hepatic steatosis on the risk for hepatocellular carcinoma (HCC) in CHB patients without excessive alcohol intake. Methods: Consecutive CHB patients who underwent liver biopsy from January 2007 to December 2015 were included. The association between hepatic steatosis (≥ 5%) and subsequent HCC risk was analyzed. Inverse probability weighting (IPW) using the propensity score was applied to adjust for differences in patient characteristics, including metabolic factors. Results: Fatty liver was histologically proven in 70 patients (21.8%) among a total of 321 patients. During the median (interquartile range) follow-up of 5.3 (2.9–8.3) years, 17 of 321 patients (5.3%) developed HCC: 8 of 70 patients (11.4%) with fatty liver and 9 of 251 patients (3.6%) without fatty liver. The five-year cumulative incidences of HCC among patients without and with fatty liver were 1.9% and 8.2%, respectively (P=0.004). Coexisting fatty liver was associated with a higher risk for HCC (adjusted hazards ratio [HR], 3.005; 95% confidence interval [CI], 1.122–8.051; P =0.03). After balancing with IPW, HCC incidences were not significantly different between the groups (P =0.19), and the association between fatty liver and HCC was not significant (adjusted HR, 1.709; 95% CI, 0.404–7.228; P =0.47). Conclusions: Superimposed NAFLD was associated with a higher HCC risk in CHB patients. However, the association between steatosis per se and HCC risk was not evident after adjustment for metabolic factors.
Abstract
Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide epidemic, and is frequently found in patients with chronic hepatitis B (CHB). We investigated the impact of histologically proven hepatic steatosis on the risk for hepatocellular carcinoma (HCC) in CHB patients without excessive alcohol intake. Methods: Consecutive CHB patients who underwent liver biopsy from January 2007 to December 2015 were included. The association between hepatic steatosis (≥ 5%) and subsequent HCC risk was analyzed. Inverse probability weighting (IPW) using the propensity score was applied to adjust for differences in patient characteristics, including metabolic factors. Results: Fatty liver was histologically proven in 70 patients (21.8%) among a total of 321 patients. During the median (interquartile range) follow-up of 5.3 (2.9–8.3) years, 17 of 321 patients (5.3%) developed HCC: 8 of 70 patients (11.4%) with fatty liver and 9 of 251 patients (3.6%) without fatty liver. The five-year cumulative incidences of HCC among patients without and with fatty liver were 1.9% and 8.2%, respectively (P=0.004). Coexisting fatty liver was associated with a higher risk for HCC (adjusted hazards ratio [HR], 3.005; 95% confidence interval [CI], 1.122–8.051; P =0.03). After balancing with IPW, HCC incidences were not significantly different between the groups (P =0.19), and the association between fatty liver and HCC was not significant (adjusted HR, 1.709; 95% CI, 0.404–7.228; P =0.47). Conclusions: Superimposed NAFLD was associated with a higher HCC risk in CHB patients. However, the association between steatosis per se and HCC risk was not evident after adjustment for metabolic factors.
참고문헌 (26)
- Schweitzer A, "Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013", Lancet, 386, pp.1546~1555 (2015)
- Beasley RP, "Hepatitis B virus. The major etiology of hepatocellular carcinoma", Cancer, 61, pp.1942~1956 (1988)
- McMahon BJ, "The natural history of chronic hepatitis B virus infection", Semin Liver Dis, 24(Suppl 1), pp.17~21 (2004)
- Hadziyannis SJ, "Hepatitis B e antigen-negative chronic hepatitis B : natural history and treatment", Semin Liver Dis, 26, pp.130~141 (2006)
- Trépo C, "Hepatitis B virus infection", Lancet, 384, pp.2053~2063 (2014)
- Sanyal AJ, "AGA technical review on nonalcoholic fatty liver disease", Gastroenterology, 123, pp.1705~1725 (2002)
- Contos MJ, "The clinicopathologic spectrum and management of nonalcoholic fatty liver disease", Adv Anat Pathol, 9, pp.37~51 (2002)
- Ascha MS, "The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis", Hepatology, 51, pp.1972~1978 (2010)
- Chan AW, "Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B", J Gastroenterol Hepatol, 32, pp.667~676 (2017)
- Chen CL, "Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B", C infection : a follow-up study in Taiwan, 2008, pp.135, 111~121
- Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
- Korean Association for the Study of the Liver(KASL), "KASL clinical practice guidelines : management of nonalcoholic fatty liver disease", Clin Mol Hepatol, 19, pp.325~348 (2013)
- WHO Expert Consultation, "Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies", Lancet, 363, pp.157~163 (2004)
- Alberti KG, "Harmonizing the metabolic syndrome : a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;International Atherosclerosis Society; and International Association for the Study of Obesity", Circulation, 120, pp.1640~1645 (2009)
- Korean Liver Cancer Study Group, "Practice guidelines for management of hepatocellular carcinoma 2009", Korean J Hepatol, 15, pp.391~423 (2009)
- Korean Liver Cancer Study Group, "2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma", Korean Journal of Radiology, 16(3), pp.465~522 (2015), 대한영상의학회[DOI]
- Bruix J, "American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma", Hepatology, 42, pp.1208~1236 (2005)
- Bruix J, "Management of hepatocellular carcinoma : an update", Hepatology, 53, pp.1020~1022 (2011)
- Bravo AA, "Liver biopsy", N Engl J Med, 344, pp.495~500 (2001)
- Ishak K, "Histological grading and staging of chronic hepatitis", J Hepatol, 22, pp.696~699 (1995)
- Yu MW, "Influence of metabolic risk factors on risk of hepatocellular carcinoma and liverrelated death in men with chronic hepatitis B : a large cohort study", Gastroenterology, 153, pp.1006~1017 (2017)
- Wang MM, "Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors", Dig Dis Sci, 59, pp.2571~2579 (2014)
- Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
- Bedossa P, "Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients", Hepatology, 56, pp.1751~1759 (2012)
- Bedossa P, "Utility and appropriateness of the fatty liver inhibition of progression(FLIP)algorithm and steatosis, activity, and fibrosis(SAF)score in the evaluation of biopsies of nonalcoholic fatty liver disease", Hepatology, 60, pp.565~575 (2014)
- Matthews DR, "Homeostasis model assessment : insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man", Diabetologia, 28, pp.412~419 (1985)